CytomX Therapeutics (NASDAQ:CTMX) Stock Gets Price Target Boost from Wedbush

CytomX Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wedbush raised its price target on CytomX Therapeutics to $12 from $11 and maintained an “outperform” rating, implying roughly 449% upside from the stock’s then-current price of $2.19.
  • Analyst opinions are mixed, but the consensus rating is “Moderate Buy” with a $12 price target; recent downgrades include Zacks Research to “hold” and Wall Street Zen to “sell.”
  • CytomX reported quarterly losses of $0.09 per share, worse than the $0.07 loss analysts expected, while revenue of $1.69 million fell short of the $10.38 million consensus estimate.
  • Five stocks to consider instead of CytomX Therapeutics.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) had its target price raised by analysts at Wedbush from $11.00 to $12.00 in a research note issued on Friday, Benzinga reports. The firm currently has an "outperform" rating on the biotechnology company's stock. Wedbush's target price suggests a potential upside of 449.20% from the company's current price.

Other research analysts have also recently issued reports about the company. Zacks Research cut CytomX Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. Guggenheim lowered their price target on CytomX Therapeutics from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Monday, August 10th. JPMorgan Chase & Co. lowered their price target on CytomX Therapeutics from $12.00 to $11.00 and set an "overweight" rating on the stock in a research report on Thursday, August 13th. Wall Street Zen cut CytomX Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, August 23rd. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of CytomX Therapeutics in a report on Friday, September 11th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, CytomX Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $12.00.

Get Our Latest Stock Report on CTMX

CytomX Therapeutics Trading Up 2.1%

Shares of CytomX Therapeutics stock traded up $0.04 during trading hours on Friday, reaching $2.19. 835,161 shares of the company's stock were exchanged, compared to its average volume of 4,662,844. The company has a 50 day moving average of $2.74 and a two-hundred day moving average of $3.83. CytomX Therapeutics has a fifty-two week low of $2.11 and a fifty-two week high of $8.21. The stock has a market cap of $476.11 million, a P/E ratio of -4.37 and a beta of 2.23.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The company had revenue of $1.69 million during the quarter, compared to the consensus estimate of $10.38 million. CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 38.46%. As a group, analysts expect that CytomX Therapeutics will post -0.40 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CytomX Therapeutics

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of CytomX Therapeutics during the 2nd quarter worth about $65,849,000. Bank of America Corp DE acquired a new position in CytomX Therapeutics in the 2nd quarter valued at about $56,560,000. Elmind Capital LP bought a new position in CytomX Therapeutics in the 2nd quarter valued at about $17,062,500. Siren L.L.C. bought a new position in CytomX Therapeutics in the 1st quarter valued at about $16,251,000. Finally, ADAR1 Capital Management LLC bought a new position in CytomX Therapeutics in the 2nd quarter valued at about $12,619,000. 67.77% of the stock is currently owned by institutional investors and hedge funds.

CytomX Therapeutics Company Profile

(Get Free Report)

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company's approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites.

CytomX's research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines.

Featured Articles

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CytomX Therapeutics Right Now?

Before you consider CytomX Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.

While CytomX Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines